Forget COVID: Moderna Is Turning Into a Cancer Company -- and Wall Street Is Taking Notice

Moderna's coronavirus vaccine generated blockbuster revenue, but demand declined in the later stages of the pandemic. The company's oncology pipeline is advancing, and a potential product may be on the horizon.